NEOK Bio, Inc., an oncology therapeutics company focused on the development of novel antibody drug conjugates (ADCs) for ...
January 21, 2026-- Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology th ...
GlobalData on MSN
D3 Bio receives FDA clearance to advance KRAS inhibitor trials
The Phase II trial will assess the early efficacy, safety and pharmacokinetics of combining elisrasib with D3S 002.
After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop ...
InvestorsHub on MSN
Boundless Bio secures FDA green light to launch cancer drug study
Boundless Bio (NASDAQ:BOLD) said it has received clearance from the Food and Drug Administration for its investigational new ...
JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the ...
3h
Bio Behavioral Health Joins PhaseWell Research to Expand Access to Neuropsychiatric Clinical Trials
PhaseWell Research ("PhaseWell"), a national clinical research site company, today announced a new partnership with Bio ...
The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...
Accelerated drug discovery and development platform Converge Bio Inc. today announced it has raised $25 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback